• United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares at USD 146.03 on June 10, 2026.
• Rothblatt sold 8,515 shares at weighted-average prices ranging from USD 539.12 to USD 557.04.
• Directly held common stock fell to 40,513 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000074), on June 11, 2026, and is solely responsible for the information contained therein.